File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: The t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: report from the International DLBCL Rituximab-CHOP Consortium Program Study

TitleThe t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: report from the International DLBCL Rituximab-CHOP Consortium Program Study
Authors
Issue Date2011
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
The 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH 2011), San Diego, CA., 10-13 December 2011. In Blood, 2011, v. 118 n. 21, abstract 949 How to Cite?
AbstractINTRODUCTION: Diffuse large B cell lymphoma (DLBCL) has a highly variable outcome, and individual risk assessment is largely based on clinical features. Gene expression profiling (GEP) stratifies patients into those with germinal center B-cell (GCB) and activated B-cell subtype (ABC) subtype with different prognoses. These groups have been shown to predict prognosis in patients treated with CHOP or R-CHOP. Conversely, the role of other recognized prognostic markers, such as BCL2 gene abnormalities or Bcl2 expression has been questioned in the new therapeutic era. MATERIALS AND METHODS: In 438 patients treated with R-CHOP for de novo DLBCL, we analyzed the tumors by immunohistochemistry for Bcl2 protein expression and by interphase fluorescence in situ hybridization (FISH) for BCL2 translocation and other abnormalities. All cases were successfully studied by GEP. The cutoff for Bcl2 protein expression, 60%, used as prognostic factor was determined using receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were assessed. RESULTS: The t(14;18)(q32;q21) was detected in 82 cases (18.7%) and BCL2 gains occurred in 63 cases (14.3%). Both t(14;18) and BCL2 gains strongly correlated with higher levels of Bcl2 protein expression (p<0.0001 for both). Presence of t(14;18) was associated with the GCB subtype (p<0.0001), whereas BCL2 gains were associated with the ABC subtype (p=0.004). BCL2 gains were not predictive of PFS in any patients' subgroups. Conversely, within the GCB subtype, patients with the t(14;18) displayed a significantly worse outcome compared to GCB patients without t(14;18) with a 5-year PFS of 45% vs 68%, respectively (p<0.0001). Outcome of patients with DLBCL associated with t(14;18) was similar to patients with the ABC subtype (45% vs 48%, p=0.30, Figure 1). No impact of the t(14;18) and BCL2 gains was observed on patients with ABC-DLBCL. Using immunohistochemistry, patients with Bcl2 positive (>60%) tumors had significantly inferior PFS in the GCB subgroup (p=0.03), but not in the ABC subgroup (p=0.54). Multivariate analysis revealed that the presence of the t(14;18), but not Bcl2 protein expression, was independent of the International Prognostic Index in predicting outcome of our patients. CONCLUSIONS: Patients with the GCB subtype and t(14;18) exhibit a significantly worse prognosis than patients without t(14;18) when treated with R-CHOP. The assessment of t(14;18) by FISH approach not only functions as a valuable prognosticator for individual risk estimation in GCB-DLBCL patients in addition to the established parameters, but also provides valuable result for therapeutic intervention.
DescriptionOpen Access Journal
This journal issue is proceedings of ASH Conference 2011
Oral Sessions - 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Clinical Determinants and Microenvironment
Persistent Identifierhttp://hdl.handle.net/10722/160395
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395

 

DC FieldValueLanguage
dc.contributor.authorVisco, Cen_US
dc.contributor.authorTzankov, Aen_US
dc.contributor.authorXu-Monette, ZYen_US
dc.contributor.authorMiranda, RNen_US
dc.contributor.authord'Amore, ESGen_US
dc.contributor.authorMontes-Moreno, Sen_US
dc.contributor.authorDybkae, Ken_US
dc.contributor.authorChiu, Aen_US
dc.contributor.authorTam, Wen_US
dc.contributor.authorOrazi, Aen_US
dc.contributor.authorZu, Yen_US
dc.contributor.authorBhagat, Gen_US
dc.contributor.authorKahl, BSen_US
dc.contributor.authorWinter, JNen_US
dc.contributor.authorWang, HYen_US
dc.contributor.authorDunphy, CHen_US
dc.contributor.authorHsi, EDen_US
dc.contributor.authorZhao, FXen_US
dc.contributor.authorGo, RSen_US
dc.contributor.authorChoi, WWLen_US
dc.contributor.authorZhou, Fen_US
dc.contributor.authorCzader, Men_US
dc.contributor.authorZhao, Xen_US
dc.contributor.authorVan Krieken, JHJMen_US
dc.contributor.authorHuang, Qen_US
dc.contributor.authorAi, Wen_US
dc.contributor.authorEtzell, JEen_US
dc.contributor.authorPonzoni, Men_US
dc.contributor.authorFerreri, AJMen_US
dc.contributor.authorPiris, MAen_US
dc.contributor.authorMøller, MBen_US
dc.contributor.authorBueso-Ramos, CEen_US
dc.contributor.authorMedeiros, LJen_US
dc.contributor.authorYoung, KHen_US
dc.date.accessioned2012-08-16T06:09:39Z-
dc.date.available2012-08-16T06:09:39Z-
dc.date.issued2011en_US
dc.identifier.citationThe 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH 2011), San Diego, CA., 10-13 December 2011. In Blood, 2011, v. 118 n. 21, abstract 949en_US
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/160395-
dc.descriptionOpen Access Journal-
dc.descriptionThis journal issue is proceedings of ASH Conference 2011-
dc.descriptionOral Sessions - 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Clinical Determinants and Microenvironment-
dc.description.abstractINTRODUCTION: Diffuse large B cell lymphoma (DLBCL) has a highly variable outcome, and individual risk assessment is largely based on clinical features. Gene expression profiling (GEP) stratifies patients into those with germinal center B-cell (GCB) and activated B-cell subtype (ABC) subtype with different prognoses. These groups have been shown to predict prognosis in patients treated with CHOP or R-CHOP. Conversely, the role of other recognized prognostic markers, such as BCL2 gene abnormalities or Bcl2 expression has been questioned in the new therapeutic era. MATERIALS AND METHODS: In 438 patients treated with R-CHOP for de novo DLBCL, we analyzed the tumors by immunohistochemistry for Bcl2 protein expression and by interphase fluorescence in situ hybridization (FISH) for BCL2 translocation and other abnormalities. All cases were successfully studied by GEP. The cutoff for Bcl2 protein expression, 60%, used as prognostic factor was determined using receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were assessed. RESULTS: The t(14;18)(q32;q21) was detected in 82 cases (18.7%) and BCL2 gains occurred in 63 cases (14.3%). Both t(14;18) and BCL2 gains strongly correlated with higher levels of Bcl2 protein expression (p<0.0001 for both). Presence of t(14;18) was associated with the GCB subtype (p<0.0001), whereas BCL2 gains were associated with the ABC subtype (p=0.004). BCL2 gains were not predictive of PFS in any patients' subgroups. Conversely, within the GCB subtype, patients with the t(14;18) displayed a significantly worse outcome compared to GCB patients without t(14;18) with a 5-year PFS of 45% vs 68%, respectively (p<0.0001). Outcome of patients with DLBCL associated with t(14;18) was similar to patients with the ABC subtype (45% vs 48%, p=0.30, Figure 1). No impact of the t(14;18) and BCL2 gains was observed on patients with ABC-DLBCL. Using immunohistochemistry, patients with Bcl2 positive (>60%) tumors had significantly inferior PFS in the GCB subgroup (p=0.03), but not in the ABC subgroup (p=0.54). Multivariate analysis revealed that the presence of the t(14;18), but not Bcl2 protein expression, was independent of the International Prognostic Index in predicting outcome of our patients. CONCLUSIONS: Patients with the GCB subtype and t(14;18) exhibit a significantly worse prognosis than patients without t(14;18) when treated with R-CHOP. The assessment of t(14;18) by FISH approach not only functions as a valuable prognosticator for individual risk estimation in GCB-DLBCL patients in addition to the established parameters, but also provides valuable result for therapeutic intervention.-
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlooden_US
dc.titleThe t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: report from the International DLBCL Rituximab-CHOP Consortium Program Studyen_US
dc.typeConference_Paperen_US
dc.identifier.emailChoi, WWL: choiwl@hkucc.hku.hken_US
dc.identifier.authorityChoi, WWL=rp00247en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros203853en_US
dc.identifier.volume118-
dc.identifier.issue21-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 130326-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats